McCourt Marion sold $2.0M of REGN

McCourt Marion (EVP Commercial) sold 2,346 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $853.56 ($850.00–$857.39, $2.00M total) across 2 trades over 2026-09-02 to 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McCourt Marion
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited impact on REGN's valuation.

02

Market read

Provides a fresh insider transaction record; useful for compliance and short‑term sentiment monitoring.

03

What to watch

The sale was pre‑arranged under a 10b5‑1 plan, reducing the likelihood of new information driving the trade.

Relevance 5/10Novelty 4/10Timing: filing date 2026-09-03

Background

Form 4 filings provide transparency on insider transactions; this filing reports a routine sale by a senior executive.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

SEC Form 4 disclosed EVP Commercial Marion McCourt sold $2.0M of REGN shares via a 10b5-1 plan.

Expected impact

Limited short-term price pressure; unlikely to move the stock materially.

Evidence & confidence

A $2M sale by an executive is a routine liquidity event; no strategic change indicated.

Market effects

Minimal impact on biotech sector; insider sales are common and not sector-wide.

No regional effect beyond REGN shareholders.

Low global relevance.

Counterpoint

Some traders may view any insider sell as a bearish signal and short the stock.

Key entities

  • Regeneron Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker REGN.

  • Marion McCourt

    Executive Vice President, Commercial at Regeneron.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.